Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Allergen-specific IgE antibodies are produced by B cells in response to allergen exposure. These antibodies bind to FcεRI receptors on mast cells and basophils. Upon re-exposure to the allergen, crosslinking of IgE on these cells triggers degranulation and the release of inflammatory mediators, leading to allergic symptoms. Allergen-specific IgE is the central mediator of Type I hypersensitivity reactions.
Neutralizes free IgE, preventing binding to FcεRI on mast cells and basophils.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Allergen-Specific Immunoglobulin E (Allergen-Specific IgE).